Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

lefradafiban

Known as: 5-((((4'-(imino(methoxycarbonyl)amino)methyl)(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-pyrrolidineacetic acid, methyl ester 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation… 
  • table III
  • table II
  • table IV
2001
2001
A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes… 
2001
2001
OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase… 
2000
2000
AIMS Oral glycoprotein IIb/IIIa inhibitors might enhance the early benefit of an intravenous agent and prevent subsequent cardiac… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2000
2000
AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal… 
1999
1999
We have used a whole blood single-platelet counting assay (WB-SPC) that is sensitive to microaggregation for monitoring GPIIb… 
1999
1999
  • Drugs in R&D
  • 1999
  • Corpus ID: 12469367
Review
1998
Review
1998
  • P. Chong
  • American journal of health-system pharmacy : AJHP…
  • 1998
  • Corpus ID: 3113775
Recent studies of the effects of glycoprotein (GP) IIb/IIIa receptor antagonists on the clinical outcomes of patients with… 
Review
1998
Review
1998
Summary Since platelet aggregation is dependent on the presence of functional GP IIb/IIIa receptors and since this receptor is… 
Highly Cited
1997
Highly Cited
1997
BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute…